Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters(University of Antwerp), Jennifer Gansert(Marqués de Valdecilla University Hospital), Simon Collins(Ghent University Hospital), Alberto Sobrero(Ospedale Policlinico San Martino), Yevhen Hotko(Ghent University Hospital), Alan Rong(Hefei University of Technology), Cornelis J.A. Punt(Utrecht University), Kelly S. Oliner(Amgen (United States)), Florian Lordick(Leipzig University), G. Wilson(Ghent University Hospital), Valentina Tzekova(Ghent University Hospital), Timothy Price(Basil Hetzel Institute), Laslo Roman(Ghent University Hospital), Thierry André(Inserm), Michel Ducreux(Université Paris-Saclay), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Andrés Cervantes(INCLIVA Health Research Institute), Emily Chan(Ghent University Hospital), Andrew Strickland(Ghent University Hospital), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta)
Cited by 1,000
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Gastric cancer
|The Lancet|2020|4.8k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k